期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌维持治疗的争议与共识 被引量：9

原文传递
导出
摘要 晚期非小细胞肺癌（non—small cell lung cancer，NSCLC）一线给予4～6个疗程的含铂双药联合化疗后，是应该“观察并且等待”获得“化疗假期”，还是应该采取更为积极的策略（维持治疗），这是近几年一直争议的话题。有些学者担心维持治疗可能导致过度治疗，患者不仅不能受益，反而会增加化疗的毒性及不良反应。
作者 周彩存 陈晓霞
机构地区 同济大学附属上海市肺科医院肿瘤科
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2012年第2期91-93,共3页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 晚期非小细胞肺癌 维持治疗 化疗后 CELL LUNG 过度治疗 不良反应
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Goldie JH,Coldman A J,Gudauskas GA.Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep,1982,66:439-449.
  • 2Day RS. Treatment sequencing, asymmetry, and uncertainty:protocol strategies for combination chemotherapy. Cancer Res,1986,46:3876-3885.
  • 3Smith IE, O' Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses ofmitomycin,vinblastine,and cisplatin.J Clin Oncol,2001,19:1336-1343.
  • 4Socinski MA,Schell MJ,Peterman A,et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage 1Ⅲ B/Ⅳ nonsmall-cell lung cancer.J Clin Oncol,2002,20:1335-1343.
  • 5yon Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.Br J Cancer,2006,95:966-973.
  • 6Gridelli C,Maione P,Rossi A,et al.Potential treatment options after first-line chemotherapy for advanced NSCLC:maintenance treatment or early second-line? Oncologist,2009,14:137-147.
  • 7Stinchcombe TE,Socinski MA.Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.J Thorac Oncol,2009,4:243-250.
  • 8Belani CP,Barstis J,Perry MC,et al.Multicenter,randomized trial for stage Ⅲ Bor Ⅳ non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.J Clin Oncol,2003,21:2933-2939.
  • 9Belani CP,Waterhouse D,Ghazal H,et al. Phase Ⅲ study of maintenance gemcitabine (G) and best supportive care (BSC)versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced nonsmall cell lung cancer (NSCLC).J Clin Oncol,2010,28 Suppl (abstr 7506).
  • 10Brodowicz T,Krzakowski M,Zwitter M,et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:a phase Ⅲ trial.Lung cancer,2006,52:155-163.

同被引文献69

  • 1吴洪斌.吉非替尼不良反应的临床表现及其处理[J].药物不良反应杂志,2006,8(1):28-30. 被引量：44
  • 2魏素菊,苑素云,刘义冰.斑蝥酸钠维生素B_6注射液体外调节细胞因子的实验研究[J].现代肿瘤医学,2007,15(9):1226-1228. 被引量：28
  • 3Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuita- ble for chemotherapy (TOPICAL) : a double-blind, place- bo-controlled, phase 3 trial [ J 1. Lancet Oncol, 2012, 13 (11) :1161-1170.
  • 4Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer [ J ~. J Natl Compr Canc Netw,2010,8 ( 7 ) :740-801.
  • 5Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as ma- inte~aance treatment in advanced non-small-cell lung canc- er: a muhicentre, randomised, placebo-controlled phase 3 study ~ J 1. Lancet Onco1,2010,11 (6) :521-529.
  • 6Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemothera- py as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802 ): a multicentre, open-label, randomised, phase 3 study[ J~. Lancet Oncol,2011,12 (8) :735-742.
  • 7Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase llI st- udy of erlotinib in combination with cisplatin and gemcit- abine non-small-cell lung cancer:the Tarceva Lung Cancer Investigation Trial [ J ~. J Clin Oncol, 2007,25 ( 12 ) : 1545- 1552.
  • 8Herbst RS,Prager D, Hermann R, et al. TRIBUTE : a phase 111 trial of erlotinib hydrochloride (OSL-774) combined with carboplatin and paelitaxel chemotherapy in advanced non-small lung cancer [ J ]. J Clin Oncol, 2005,23 ( 25 ) : 5892-5899.
  • 9Takeda K, Hida T, Sato T, et al. Randomized phase 111I trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung canc- er:Results of a West Japan Thoracic Oncology Group trial ( WJTOG0203 ) [ J ]. J Clin Onco1,2010,28 (5) : 753-760.
  • 10Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN : A do- uble-blind, randomized, phase Ill study of maintenance erlo- tinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC[ J~. J Clin Oncol,2009,27(15s) :8001.

引证文献9

二级引证文献41

中华结核和呼吸杂志
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部